Economic evaluation of pharmaco- and behavioral therapies for smoking cessation: a critical and systematic review of empirical research.
Economic evaluations are an important tool to improve our understanding of the costs and effects of health care services and to create sustainable health care systems. This article critically assesses empirical evidence from economic evaluations of pharmaco- and behavioral therapies for smoking cessation. A comprehensive literature review of PubMed and the British National Health Service Economic Evaluation Database was conducted. The search identified 15 articles on nicotine-based pharmacotherapies, 12 articles on nonnicotine based pharmacotherapies, no articles on selegiline, and 10 articles on brief counseling for smoking cessation treatment. Results show that both pharmaco- and behavioral therapies for smoking cessation are cost-effective or even cost-saving. The review highlights several shortcomings in methodology and a lack of standardization of current economic evaluations. Efforts to improve methodology will help make future studies more comparable and increase the evidence base so that such evaluations can be more useful to public health practitioners and policy makers.
School of Public Health, School of Medicine, Yale University, New Haven, Connecticut 06520-8034, USA. jennifer.ruger@yale.edu
Jennifer Prah
JP
Ruger
Christina M
CM
Lazar
D015928:Cognitive Behavioral Therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D004358:Drug Therapy / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D011634:Public Health; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods*; D016896:Treatment Outcome